NASDAQ:ANIP

ANI Pharmaceuticals Competitors

$34.14
+1.11 (+3.36 %)
(As of 04/14/2021 01:44 PM ET)
Add
Compare
Today's Range
$33.64
Now: $34.14
$34.14
50-Day Range
$28.40
MA: $31.82
$36.14
52-Week Range
$23.55
Now: $34.14
$52.22
Volume172 shs
Average Volume58,021 shs
Market Capitalization$422.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) Vs. AUPH, HRMY, QURE, ADCT, MYOV, and HRTX

Should you be buying ANIP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ANI Pharmaceuticals, including Aurinia Pharmaceuticals (AUPH), Harmony Biosciences (HRMY), uniQure (QURE), ADC Therapeutics (ADCT), Myovant Sciences (MYOV), and Heron Therapeutics (HRTX).

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and ANI Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$320,000.005,066.18$-123,850,000.00($0.89)-14.29
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Aurinia Pharmaceuticals and ANI Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurinia Pharmaceuticals01702.88
ANI Pharmaceuticals01202.67

Aurinia Pharmaceuticals currently has a consensus target price of $28.50, suggesting a potential upside of 123.00%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than ANI Pharmaceuticals.

Profitability

This table compares Aurinia Pharmaceuticals and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%
ANI Pharmaceuticals-11.92%19.01%8.15%

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Aurinia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Harmony Biosciences and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than Harmony Biosciences.

Insider and Institutional Ownership

50.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Harmony Biosciences and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
ANI Pharmaceuticals-11.92%19.01%8.15%

Analyst Recommendations

This is a summary of recent ratings for Harmony Biosciences and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences00303.00
ANI Pharmaceuticals01202.67

Harmony Biosciences presently has a consensus target price of $51.6667, suggesting a potential upside of 77.85%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares uniQure and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million216.07$-124,200,000.00($3.11)-11.24
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

uniQure has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares uniQure and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
ANI Pharmaceuticals-11.92%19.01%8.15%

Analyst Recommendations

This is a summary of recent ratings for uniQure and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
ANI Pharmaceuticals01202.67

uniQure presently has a consensus target price of $68.4615, suggesting a potential upside of 95.49%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats uniQure on 8 of the 15 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares ADC Therapeutics and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$2.34 million720.42$-116,480,000.00($2.36)-10.37
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.9% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ADC Therapeutics and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADC TherapeuticsN/AN/AN/A
ANI Pharmaceuticals-11.92%19.01%8.15%

Analyst Recommendations

This is a summary of recent ratings for ADC Therapeutics and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADC Therapeutics01402.80
ANI Pharmaceuticals01202.67

ADC Therapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 90.23%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats ADC Therapeutics on 7 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Myovant Sciences and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-5.25
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Myovant Sciences and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
ANI Pharmaceuticals-11.92%19.01%8.15%

Analyst Recommendations

This is a summary of recent ratings for Myovant Sciences and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
ANI Pharmaceuticals01202.67

Myovant Sciences presently has a consensus target price of $31.1667, suggesting a potential upside of 74.60%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Myovant Sciences' higher probable upside, analysts plainly believe Myovant Sciences is more favorable than ANI Pharmaceuticals.

Summary

ANI Pharmaceuticals beats Myovant Sciences on 8 of the 13 factors compared between the two stocks.

Heron Therapeutics (NASDAQ:HRTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Heron Therapeutics and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
ANI Pharmaceuticals-11.92%19.01%8.15%

Analyst Recommendations

This is a summary of recent ratings for Heron Therapeutics and ANI Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01502.83
ANI Pharmaceuticals01202.67

Heron Therapeutics presently has a consensus target price of $29.60, suggesting a potential upside of 70.41%. ANI Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 36.74%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than ANI Pharmaceuticals.

Volatility & Risk

Heron Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Heron Therapeutics and ANI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million10.90$-204,750,000.00($2.50)-6.96
ANI Pharmaceuticals$206.55 million2.04$6.09 million$4.467.65

ANI Pharmaceuticals has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


ANI Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.72+0.6%$1.63 billion$320,000.00-8.65Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.90+1.5%$1.62 billionN/A0.00Analyst Revision
uniQure logo
QURE
uniQure
1.7$34.96+0.2%$1.57 billion$7.28 million-9.27
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.47+7.1%$1.57 billion$2.34 million-10.37Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.69+3.5%$1.55 billionN/A-6.30Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.41+4.3%$1.52 billion$145.97 million-7.05Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$25.64+2.4%$1.51 billion$175.34 million-15.08Analyst Report
Analyst Revision
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$37.22+12.8%$1.51 billionN/A0.00Analyst Upgrade
Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.4$61.88+3.5%$1.49 billionN/A0.00Increase in Short Interest
Gap Down
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.51+2.4%$1.47 billionN/A0.00Insider Selling
Increase in Short Interest
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.67+5.2%$1.45 billion$82.27 million-18.71News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.93+0.3%$1.44 billionN/A-149.71Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.87+2.9%$1.43 billionN/A0.00Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$26.60+4.5%$1.43 billionN/A0.00Increase in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.79+2.1%$1.42 billion$6.20 million-14.38
ATBPD
Antibe Therapeutics
0.1$3.66+0.0%$1.42 billion$7.51 million-6.10Gap Down
Endo International logo
ENDP
Endo International
1.3$6.32+3.3%$1.41 billion$2.91 billion-9.29
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.44+2.2%$1.39 billionN/A-3.08Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$27.75+0.9%$1.37 billion$19.89 million-13.09
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.79+4.8%$1.37 billion$4.23 million-20.59Increase in Short Interest
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.37+3.7%$1.34 billion$73.41 million-4.52Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$33.18+3.2%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$36.19+0.5%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$34.76+6.6%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.74+9.2%$1.29 billion$29.54 million-8.15News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$22.74+0.7%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.92+0.1%$1.22 billionN/A-2.78Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.53+4.3%$1.21 billionN/A-19.18
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.69+4.8%$1.21 billion$4.23 million-9.32News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.96+4.5%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.67+0.3%$1.18 billion$261.02 million5.95
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$26.01+16.8%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.53+1.5%$1.17 billion$59.70 million-195.30
NKTX
Nkarta
1.8$36.12+1.6%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.28+3.1%$1.13 billion$35.22 million-7.50
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.98+1.6%$1.12 billion$230,000.00-12.08News Coverage
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.25+6.3%$1.12 billion$42.12 million-12.78Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$27.00+5.3%$1.11 billionN/A-9.09Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$17.95+2.6%$1.08 billion$111.81 million-7.54
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.20+0.2%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.33+3.9%$1.07 billionN/A-6.89
Zogenix logo
ZGNX
Zogenix
1.7$19.49+2.1%$1.06 billion$3.65 million-2.05
MannKind logo
MNKD
MannKind
1.4$4.48+6.0%$1.05 billion$63.04 million-21.33Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.11+5.3%$1.05 billionN/A-8.53Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.35+2.6%$1.04 billion$120,000.00-3.83Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.91+3.6%$1.04 billion$20.79 million-14.11Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.04+1.9%$1.04 billionN/A-6.92Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.97+2.8%$1.02 billionN/A-8.61
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68+2.5%$996.70 million$122.47 million-27.85Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.08+6.7%$993.66 million$1.52 million-11.74Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.